Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01751906 · ClinicalTrials.gov registry record · NA
ABSORB III Randomized Controlled Trial (RCT)
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 2,008
- Enrollment target
NCT01751906: Completed NA study, sponsored by Abbott Medical Devices.
NCT01751906 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,008 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01751906, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,008 participants
- Enrollment target
Study Summary
The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS). The ABSORB III includes additional two trials i.e. ABSORB III PK (pharmacokinetics) sub-study and ABSORB IV RCT trial which are maintained under one protocol because both trial designs are related, ABSORB IV is the continuation of ABSORB III and the data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS.
Primary Outcome
TLF is defined as composite of Cardiac Death, Myocardial Infarction (per protocol-defined MI definition), attributable to Target Vessel (TV-MI), or Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Interventions
- DEVICE XIENCE
- DEVICE Absorb BVS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,008 participants |
| Start Date | 2012-12 |
| Est. Completion | 2020-10 |
| Phase | NA |
What the finished NCT01751906 record still lists
NCT01751906 is an interventional study that assigns participants to a tested intervention. Its 2,008 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 2 interventions - of which XIENCE is the first listed.
NCT01751906 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01751906 about?
NCT01751906 is a clinical study titled "ABSORB III Randomized Controlled Trial (RCT)". The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS). The ABSORB III includes additional two trials i.e. ABSORB III PK (pharmacokinetics) sub-study and A...
What is the current status of trial NCT01751906?
This trial is currently completed. It is a NA study. The enrollment target is 2,008 participants. The study started on 2012-12. Estimated completion is 2020-10.
What interventions are being tested in trial NCT01751906?
The interventions under investigation include: XIENCE (DEVICE), Absorb BVS (DEVICE).
Who is sponsoring clinical trial NCT01751906?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01751906's enrollment target sits among peer trials
2,008 52nd of 2000 higher than 1,949 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia